NEWS HIGHLIGHTS
Published Studies Related to Bupivacaine and Epinephrine (Bupivacaine / Epinephrine Dental)
Bupivacaine extended-release liposome injection exhibits a favorable cardiac
safety profile. [2012]
novel formulation of bupivacaine... CONCLUSIONS: A focused assessment of ECG data from a phase 2 study and cardiac
Triple-blind randomized clinical trial of time until sensory change using 1.5%
mepivacaine with epinephrine, 0.5% bupivacaine, or an equal mixture of both for
infraclavicular block. [2012]
by 20% or more versus 0.5% bupivacaine alone (bupivacaine)... CONCLUSIONS: Mixing 1.5% mepivacaine (with epinephrine) with 0.5% bupivacaine
Bupivacaine 0.5 % versus articaine 4 % for the removal of lower third molars. A crossover randomized controlled trial. [2011.12.06]
Objective: To compare the anesthetic action of 0.5% bupivacaine in relation to 4% articaine, both with 1:200,000 epinephrine, in the surgical removal of lower third molars. As a secondary objective hemodynamic changes using both anesthetics were analyzed...
Addition of epinephrine to epidural bupivacaine infusions following initiation of labor analgesia with epidural fentanyl. [2011.06]
STUDY OBJECTIVE: To evaluate the analgesic effects of the addition of epinephrine to a bupivacaine epidural infusion in early labor after a fentanyl bolus, following a lidocaine-epinephrine test dose... CONCLUSIONS: The administration of 0.625 mg/mL bupivacaine with epinephrine 5 mug/mL at 10 mL/hr, compared with plain 0.625 mg/mL bupivacaine at 10 mL/hr, provided a longer time to re-dose, decreased pain scores at two time intervals, and had no significant difference in duration of labor or side effects. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Comparative study of two local anesthetics in the surgical extraction of mandibular third molars: bupivacaine and articaine. [2011.05.01]
OBJECTIVE: The third molar extraction is one of the most common surgical procedures in oral surgery and is usually accompanied by postoperative discomfort. It has been suggested that the longer duration of action of bupivacaine associated with the residual analgesia and the gradual onset of pain, could decrease the need for analgesics during the postoperative period. This study aims to compare the efficacy and safety of bupivacaine and articaine as local anesthetics for the extraction of mandibular third molars and to check whether bupivacaine produced residual analgesia... CONCLUSION: It can be concluded that articaine seems to be a more appropriate anesthetic for the extraction of mandibular third molars due to the shorter duration of the anesthetic effect in the soft tissues, lower pain reported by patients during the immediate postoperative period and the personal preference of patients for this drug.
Clinical Trials Related to Bupivacaine and Epinephrine (Bupivacaine / Epinephrine Dental)
Bupivacaine Effectiveness and Safety in SABER⢠Trial [Recruiting]
This is a research study testing SABER™-Bupivacaine (an experimental pain-relieving
medication). SABER™-Bupivacaine is designed to continuously deliver bupivacaine, a common
local anesthetic, for a few days in order to treat local post-surgical pain.
The purpose of this study is to investigate safety (side effects) associated with the use of
SABER™-Bupivacaine and how well it works in reducing pain and opioid-related side effects
following various kinds of abdominal surgeries.
Epidural Fentanyl-bupivacaine Versus Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor [Not yet recruiting]
Epidural analgesia is widely regarding as the most effective analgesic strategy for labor
pain. Modern practice is to utilize dilute local anesthetics as a continuous infusion along
with an opioid, e. g., our common "recipe" of 12 ml/hr of 0. 0625% bupivacaine with 2
micrograms/ml fentanyl, after the initial dose to maintain patient comfort until delivery.
This dose of the infusion often provides adequate comfort without interfering with the
mobility of the patient and her ability to effectively push during delivery. However, this
low dose epidural infusion strategy often results in recurrence of pain after an initial
pain free period.
This breakthrough pain is treated by administering small boluses of analgesics via the
epidural catheter. The pain occurring in labor is initially of visceral origin and is
mediated by pain fibers originating from the low thoracic and upper lumbar segments of the
spinal cord. As labor progresses to the late first phase (also known as transitional stage),
pain sensations originating from the distension of the pelvic floor, vagina and perineum
adds a somatic component to labor pain. This type of breakthrough pain is often difficult to
treat.
Although requests from patients to alleviate late stage breakthrough pain are common, no one
knows the most effective strategy for pain management in this stage of labor. This study is
designed to compare the efficacy of two treatments for controlling late first stage
breakthrough pain during labor with an epidural infusion in place: clonidine-bupivacaine
versus fentanyl-bupivacaine.
Women who have labor epidural analgesia in place will be enrolled to be randomized if and
when they present with breakthrough pain in the late first stage or second stage of labor
(⥠8 cm dilated). They will receive 8 ml of a solution containing 10 mg bupivacaine and 75
micrograms of either fentanyl (an opioid or "narcotic") or clonidine (an "alpha-2 agonist
known to be effective as an epidural analgesic).
Pain relief, labor progress and outcome will be assessed to compare fentanyl versus
clonidine.
It is the hypothesis of this study that clonidine added to bupivacaine is a better analgesic
than fentanyl added to bupivacaine for breakthrough pain in advanced labor.
Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain [Recruiting]
This study will evaluate the efficacy and safety of Bupivacaine TTS (Bupivacaine patch)
compared to placebo in patients with chronic low back pain.
2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula [Recruiting]
Bupivacaine Pain Pumps to Decrease Mastectomy Post-Operative Pain [Not yet recruiting]
This double-blind, randomized, controlled clinical trial comparing patient-reported pain and
pain medication/narcotic use between patients randomized to treatment (bupivacaine) or
placebo (saline) delivered via pain pump to the mastectomy site. Candidates will have chosen
to have a mastectomy on one side immediately followed with tissue expander placement breast
reconstruction.
Patients will be randomized 1: 1 to bupivacaine- (treatment) or saline-(placebo) filled
percutaneously-placed pain pumps; neither the participants nor the study staff will know
participants' treatment. Data on patient-perceived pain and pain medication use will be
collected before surgery, during surgery, and after surgery on Days 1, 2, 3, 7, and 90, and
at Years 2 and 4 by phone.
The investigators hypothesize that patients randomized to the treatment (bupivacaine) group
will have significantly lower pain scores and use less pain medicine than patients who
receive placebo during the first 90 days following their surgery. The Year 2 and Year 4
follow-ups are included as tertiary endpoints to capture differences in chronic pain, and
patients will be asked to complete the same questionnaires as at the Day 90 follow up.
|
